Avadel Pharmaceuticals (AVDL) Retained Earnings: 2009-2021
Historic Retained Earnings for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to -$447.8 million.
- Avadel Pharmaceuticals' Retained Earnings fell 31.10% to -$557.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$557.8 million, marking a year-over-year decrease of 31.10%. This contributed to the annual value of -$447.8 million for FY2021, which is 16.55% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Retained Earnings stood at -$447.8 million for FY2021, which was down 16.55% from -$384.2 million recorded in FY2020.
- Over the past 5 years, Avadel Pharmaceuticals' Retained Earnings peaked at -$262.7 million during FY2017, and registered a low of -$447.8 million during FY2021.
- Its 3-year average for Retained Earnings is -$407.7 million, with a median of -$391.2 million in 2019.
- In the last 5 years, Avadel Pharmaceuticals' Retained Earnings increased by 17.86% in 2017 and then plummeted by 36.28% in 2018.
- Yearly analysis of 5 years shows Avadel Pharmaceuticals' Retained Earnings stood at -$262.7 million in 2017, then tumbled by 36.28% to -$358.0 million in 2018, then dropped by 9.28% to -$391.2 million in 2019, then climbed by 1.80% to -$384.2 million in 2020, then dropped by 16.55% to -$447.8 million in 2021.